BioCentury
ARTICLE | Clinical News

AZ's Fasenra fails in Phase III COPD study

May 18, 2018 2:13 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease.

The company expects data this quarter from TERRANOVA, a second Phase III trial of Fasenra in the indication. AZ said it will determine next steps for Fasenra in COPD after conducting a full evaluation of both trials...